Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

127
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
127

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Innovative Buccal Nanofibers for Dual Delivery of Tadalafil and Dapoxetine for Erectile Dysfunction and Premature Ejaculation Conditions.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Treatment of residual and phantom limb pain using percutaneous ablation: a systematic review and meta-analysis.

Frontiers in rehabilitation sciences·2026
Same author

Electrospun PVA Nanofibers Co-Loaded with Atorvastatin and Zinc Oxide for Antibacterial and In Vitro Wound Healing Applications.

Biomedicines·2026
Same author

Bacteriophages as Therapeutic Agents for Pulmonary Infections: From Biological Principles to Clinical Applications.

Pharmaceutics·2026
Same author

Influence of Impregnation Conditions on Tenoxicam Solubility and Loading into γ-Cyclodextrin Metal-Organic Frameworks: A Box-Behnken Design Approach.

Pharmaceutics·2026
Same author

Formulation and administration timing of lipid derivatized JAK-inhibitor and corticosteroid modulate saRNA-LNP inflammation and expression.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Silicone oil in protein drug products and its implications for formulation stability.

Advanced drug delivery reviews·2026
Same journal

Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD).

Advanced drug delivery reviews·2026
Same journal

Lysosome-targeting degrader delivery system: from formulation design to biomedical applications.

Advanced drug delivery reviews·2026
Same journal

Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities.

Advanced drug delivery reviews·2026
Same journal

Optimizing macrophage-targeted intracellular delivery systems for safe and effective immunotherapies.

Advanced drug delivery reviews·2026
Same journal

Light-controlled CRISPR-dCas9 epigenome editing: advanced drug-delivery strategies and oncology applications.

Advanced drug delivery reviews·2026
See all related articles

Related Experiment Video

Updated: Dec 17, 2025

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications
08:19

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications

Published on: November 17, 2015

18.4K

Lipid-based nanoparticle technologies for liver targeting.

Roland Böttger1, Griffin Pauli1, Po-Han Chao1

  • 1Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, British Columbia V6T 1Z3, Canada.

Advanced Drug Delivery Reviews
|June 24, 2020
PubMed
Summary
This summary is machine-generated.

Lipid nanoparticles offer improved liver drug delivery, overcoming limitations of traditional therapies for liver diseases like hepatitis and cirrhosis. This review explores advancements in lipid-based nanoparticles for targeted liver treatments.

Keywords:
HepatitisHepatocellular carcinomaLipid nanoparticleLiposomeLiver fibrosisLiver targetingNiosomeSolid lipid nanoparticles

More Related Videos

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
09:41

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

24.7K
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.3K

Related Experiment Videos

Last Updated: Dec 17, 2025

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications
08:19

Solid Lipid Nanoparticles SLNs for Intracellular Targeting Applications

Published on: November 17, 2015

18.4K
Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
09:41

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

24.7K
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

9.3K

Area of Science:

  • Hepatology and Nanomedicine
  • Drug Delivery Systems

Background:

  • Liver diseases pose a significant global health burden, causing millions of deaths annually.
  • Current pharmacological treatments for liver conditions suffer from poor drug concentration at the target site and systemic side effects.
  • Targeted delivery to specific liver cells is often necessary for effective treatment of various liver diseases.

Purpose of the Study:

  • To review recent advancements in lipid-based nanoparticles for liver-targeting drug delivery.
  • To discuss various lipid nanoparticle formulations, including solid-lipid nanoparticles, liposomes, niosomes, and micelles.
  • To highlight challenges and future prospects in the field of liver-targeted nanomedicine.

Main Methods:

  • Literature review of recent developments in lipid-based liver-targeting technologies.
  • Analysis of nanoparticle formulations such as solid-lipid nanoparticles, liposomes, niosomes, and micelles.
  • Discussion of passive and active targeting strategies for drug delivery to the liver.

Main Results:

  • Lipid nanoparticles demonstrate significant potential for both passive and active targeting of drugs to the liver.
  • The FDA approval of ONPATTRO signifies a breakthrough in liver-targeting lipid nanoparticle technology.
  • Numerous promising lipid-based nanocarrier technologies are emerging for liver disease treatment.

Conclusions:

  • Lipid nanoparticles represent a promising strategy to enhance therapeutic efficacy and reduce side effects in liver disease treatment.
  • Continued research and development in lipid-based nanocarriers are crucial for addressing unmet needs in hepatology.
  • The field anticipates further innovations and clinical translation of liver-targeting nanomedicines.